Prasol Chemicals reported robust Q1 FY27 results with a 36% revenue jump to Rs 433.6 crore and a 151% rise in profit after tax to Rs 61 crore. Driven by operational improvements at the Mahad plant and a better product mix, the company has announced a phased Rs 500-600 crore expansion plan. Investors should track margin normalization and the execution of upcoming capacity projects.
Prasol Chemicals Reports 151% PAT Growth in Q1 FY27
Revenue stands at Rs 433.6 crore; EBITDA touches Rs 90.3 crore.
Reader Takeaway: Strong operational turnaround and expansion plans drive growth, though management warns of near-term margin normalization.
What just happened
Prasol Chemicals has posted stellar Q1 FY27 financial results, headlined by a 151% year-on-year surge in Profit After Tax (PAT) to Rs 61 crore. Revenue from operations climbed 36% to Rs 433.6 crore, supported by an EBITDA of Rs 90.3 crore. The company achieved a strong EBITDA margin of 20.8% during the period.
Why this matters
The results highlight the successful turnaround of the company's Mahad manufacturing facility, which reached record production levels this quarter. Additionally, the shift toward higher-value secondary and tertiary derivatives in the acetone and phosphorous value chains has significantly bolstered profitability.
Management Guidance
The company has set a revenue target of Rs 1,550–1,650 crore and an EBITDA target of Rs 240–250 crore for FY27. These projections exclude the impact of volatile price fluctuations and foreign currency variances.
Expansion Strategy
Prasol Chemicals has unveiled a long-term two-phase capex plan:
- Phase I: A Rs 250–300 crore investment in existing products aimed at generating Rs 500–550 crore in additional revenue over two years.
- Phase II: A Rs 250–300 crore investment focused on new R&D products, with spending slated to commence in the second half of FY28.
- Long-term Outlook: The company aims to achieve revenue of Rs 2,800–3,000 crore within the next five years.
Risks to watch
Investors should note that the current 20.8% EBITDA margin was artificially boosted by roughly Rs 25 crore due to geopolitical supply chain factors and currency fluctuations. Management has explicitly cautioned that these margins are likely to normalize in the coming quarters.
What to track next
Success hinges on the execution of the capacity expansion projects and the ability to maintain market share as temporary tailwinds fade.